Study summary · research use only
Endometriosis: the effects of dienogest
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This systematic review addressed the effects of dienogest for treating endometriosis in women of reproductive age. The abstract notes ectopic endometrial tissue occurs in 2% to 6% of reproductive-age women, up to 60% of those with dysmenorrhoea, and up to 30% with subfertility, peaking around 40 years, though symptoms may not correlate with laparoscopic findings. It states the authors searched Medline, Embase and The Cochrane Library up to June 2014, included harms alerts from the FDA and UK MHRA, and included Five studies with a GRADE evaluation, presenting information on dienogest versus placebo, gonadorelin analogues, combined oral contraceptives, and other progestogens.
Abstract
Ectopic endometrial tissue is found in 2% to 6% of women of reproductive age, in up to 60% of those with dysmenorrhoea, and in up to 30% of women with subfertility, with a peak incidence at around 40 years of age. However, symptoms may not correlate with laparoscopic findings. We conducted a systematic review and aimed to answer the following clinical question: What are the effects of dienogest for the treatment of endometriosis? We searched: Medline, Embase, The Cochrane Library, and other important databases up to June 2014 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). Five studies were included. We performed a GRADE evaluation of the quality of evidence for interventions. In this systematic review we present information relating to the effectiveness and safety of the following interventions: dienogest versus placebo or no treatment; dienogest versus gonadorelin analogues; dienogest versus combined oral contraceptives; dienogest versus other progestogens.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.